Introduction Pharmacokinetics
The pharmacokinetics of the aminoglycosides are rela-Most antibiotics, such as the b-lactams, macrolides and tively simple. These drugs are hydrophilic with low quinolones have a wide therapeutic index and therefore protein binding, and are eliminated renally. They have do not require therapeutic drug monitoring. Some, such no stereoisomerism and are not subject to genetic as the aminoglycosides and vancomycin, have a narrow polymorphism. The volume of distribution ( V ) approxitherapeutic index, and toxicity may be severe and mates that of the extracellular fluid volume, and the irreversible. Therapeutic drug monitoring may be approclearance (CL) that of the glomerular filtration rate [2] . priate for these drugs. Other drugs such as teicoplanin,
The l z -phase t 1/2 is approximately 2.5 h in patients with flucloxacillin and the antifungal agents itraconazole, normal renal function, although there is a slow terminal flucytosine and fluconazole are monitored in certain elimination phase of 100-150 h, related to distribution circumstances.
into a 'deep compartment'. Aminoglycoside pharmacokinetics vary markedly The aminoglycosides according to the state of the disease that is being treated. There is a strong case for monitoring aminoglycoside Infections are associated with altered hydration and concentrations [1] . The recent move to once-daily dosing permeability of biological barriers. The V and CL may has resulted in the need to re-evaluate monitoring therefore change dramatically during therapy. Severe strategies.
infection, or burns, can be associated with an increased V, which may require higher doses to achieve desired clearance, which may subsequently improve during fluid There is little need for monitoring peak concentrations during once-daily dosing. Peak concentrations will always replacement and resolution of the infection.
be well in excess of those seen during multiple-daily dosing and therefore within the useful range of bactericidal Why monitor aminoglycosides? effect of most bacteria (usually 5-10 times the MIC). Peak concentration measurement is therefore unnecessary The aminoglycosides have a low therapeutic index. Bactericidal efficacy is directly related to peak concen-except for pharmacokinetic dose individualisation [12] . trations (concentration-dependent killing ) while toxicity is related to total drug exposure [1]. Nephrotoxicity Individualisation of therapy (usually reversible) and ototoxicity (often irreversible) are the major forms of toxicity [5] .
Various methods of dose prediction have been used successfully. A summary of these can be found in Begg The desired plasma concentration-time profile for aminoglycosides differs from that of most other drugs et al.
[1] and Morike et al. [13] . Nomograms relating dosing to estimates of renal function were the first involved in therapeutic drug monitoring. For most drugs the aim is to have minimal fluctuations (i.e. a flat profile) attempts to individualise dosing, utilising the pharmacokinetic relationship between aminoglycoside clearance within the dosing interval to keep the concentrations within a 'therapeutic range'. A single plasma concentration and renal function. The next dosing method to gain favour was the dose-measurement, representative of accumulation, is usually all that is required for monitoring.
individualisation of Sawchuk & Zaske, [14] based on a one-compartment pharmacokinetic model. The advan-For the aminoglycosides, the desired concentrationtime profile includes a high peak concentration (for tage of this method was that after the first dose, future doses could be based upon an assessment of the patient's efficacy) followed by a low trough concentration (to prevent accumulation). The dose interval is substantially own pharmacokinetics (i.e. V and CL) for the relevant aminoglycoside. This method was shown to have advan-longer than the half-life. For therapeutic drug monitoring of the aminoglycosides, it has been traditional to monitor tages over nomograms and methods based on physician intuition, in terms of achieving desired peak and trough both a peak and a trough concentration. With the recent move to once-daily dosing, this approach needs to be concentrations [15, 16] . Bayesian methods have also been used in the dose prediction of aminoglycosides [17] . reconsidered.
These have the advantage of obtaining useful information from a smaller number of samples than with the Sawchuk Therapeutic ranges & Zaske approach [14, but in practice performance is similar for the two approaches. For many years, peak concentrations of 6-10 mg l −1 and trough concentrations of ∏2 mg l −1 were advocated for With the advent of once-daily dosing, the scene has virtually returned to the formative years of aminoglycoside gentamicin, tobramycin and netilmicin, with double these values for amikacin. SI units are not used because dosing. Most proponents of once-daily dosing have simply employed an arbitrary initial dose, usually gentamicin is not a single entity but a mixture of substances with differing side groups. It, therefore, does 3-7 mg kg −1 day −1 , based on the total amount that would have been prescribed over 24 h during multiple-not have a molecular weight and so measurement is in mass rather than molar units. Although this does not daily dosing. This approach to choice of dose seems reasonable, at least for the starting dose. It remains unclear pertain to tobramycin or netilmicin, the same units are used for convenience. The therapeutic ranges have been how drug concentrations measured for monitoring should be interpreted, and indeed at what time points drug based largely on studies that have demonstrated poor outcome associated with suboptimal peak concentrations concentrations should be measured. Some groups [12, 18, 19,] have advocated sampling at [6-8].
There are no clearly established therapeutic ranges for a time or times earlier than 24 h after the dose when the concentration is still measurable. The exact timing of once-daily dosing. Some groups have arbitrarily suggested that trough concentrations should be less than 2, 1 or these samples can vary in relation to renal function. MacGowan & Reeves [18] proposed the measurement of 0.5 mg l −1 [9-11]. However, there is no rationality for this approach because concentrations at 24 h will be a single sample at 8 h. However, it was unclear how dosing should proceed as a result of this estimate, although unrecordable, using conventional assay technology, in patients with normal renal function [12] . Concentrations this method would lend itself to Bayesian forecasting. Nicolau et al. [19] proposed a dose of 7 mg kg −1 followed of 0.5-2 mg l −1 at 24 h would indicate an overdose in these patients. Clearly the concept of a trough concen-by the measurement of a single serum concentration between 6 and 14 h after the first dose. This concentration tration is not relevant to once-daily dosing.
is compared with a nomogram which indicates whether or after a bolus dose to allow for distribution to be complete. The exact time of sampling is not important the dose interval should be 24, 36 or 48 h. Although dose intervals longer than 24 h make good theoretical but it should be recorded accurately.
The ideal time to measure the trough concentration is sense, there is little clinical evidence to support this. A recent report noted an 18% incidence of ototoxicity the end of the dosage interval. Any time within 0.5 h before the next dose is close enough in practice. The (5/28) in patients with haematological malignancies treated using this approach [20] . This is of some concern exact time should be recorded to allow pharmacokinetic interpretation. For once-daily dosing, the timing of and suggests that some patients may be receiving excessive doses.
sampling is less clear and is dependent on the method of dose individualisation to be followed. Begg et al. [12] suggest a target area under the curve (AUC) approach, based on the notion that the same total How often to sample is also an important question. Aminoglycoside therapy is not usually for longer than 7 dose should be given over 24 h as would be given using dose-individualisation with multiple-daily dosing. In order days except for bacterial endocarditis, or by inhalation for cystic fibrosis. With multiple-daily dosing frequency of to assess the AUC in a given patient, measuring a concentration at or around 1 h post-infusion and a second monitoring should reflect this clinical situation; i.e. individualised-more often if unstable, less often if stable. concentration somewhere between 6 and 22 h after the first dose is advocated, the time of the second sample With once-daily dosing it is logical to follow the same rules until new information allows these rules to be adjusted in relation to renal function [12] . From these two concentrations and assuming a one-compartment re-formulated. For longer term therapy, such as for bacterial endocar-model, the AUC is calculated. Subsequent doses can be adjusted to achieve any desired AUC. The desired target ditis, repeat monitoring may be performed at increasing intervals if the measured concentrations are relatively AUC related to doses of 5, 6 and 7 mg kg −1 day −1 in a patient with a population mean value for V of 0.25 l kg −1 stable. Since the target concentrations for the treatment of endocarditis are often lower than conventional target and CL of 4 l h −1 are 72, 86 and 101 mg l −1 h. Bayesian approaches can be used with the AUC method [21] and concentrations, the need for stringent monitoring may be less. The aminoglycosides are used in this context more have the advantage that useful information can be obtained from a single measured concentration although for a greater than additive effect with a b-lactam antibiotic given concurrently than for primary bactericidal efficacy. greater accuracy can be achieved if two concentrations are measured.
Methods of analysis Dosing in renal impairment
The aminoglycosides are generally analysed using immunoassays such as EMIT (Enzyme Multiplied The pharmacokinetics of the aminoglycosides are altered predictably when glomerular filtration is impaired.
Immunoassay Technique Syva and Behring diagnostic products, CA, USA) or FPIA (Fluorescence Polarization Patients with renal dysfunction, elderly patients and neonates will often have impaired clearance and dosing Immunoassay; Abbott, Abbott Park, IL, USA). Some aminoglycosides, such as tobramycin, netilmicin and should allow for this. It should be noted that although there is a close relationship between aminoglycoside amikacin, can be analysed using h.p.l.c., but this is not feasible for gentamicin because it is not a single substance. clearance and clinical estimates of renal function such as calculated creatinine clearance, this relationship is by no
The EMIT and FPIA assays are relatively cheap, are not labour intensive, and have good reproducibility. They are means exact and extrarenal losses, such as through sequestration into third spaces and removal of fluid from not particularly sensitive, however. The limits of quantification are around 0.29 mg l −1 for the FPIA assay and third spaces, can also occur [22] .
Once-daily dosing during increasing renal impairment 0.25 mg l −1 for the EMIT assay, levels which may be low enough for monitoring of trough concentrations is complicated since the concentration-time profile approaches that of a continuous infusion. Therefore, the using older dosing regimens but not low enough for assessing trough concentrations during once-daily amino-advantage of once-daily dosing (high peak concentrations followed by a decline to unrecordable concentrations) is glycoside dosing.
There are various quality assurance programmes (QAP) progressively lost with greater renal dysfunction.
available worldwide. In Australasia the main QAP is that of the Royal College of Pathologists of Australia. In the
Sampling times
United Kingdom, the equivalent is UKNEQAS Scheme organised by the Antimicrobial Reference Laboratory, With multiple-daily dosing, peak concentrations should be measured at least 0.5 h after the end of the infusion Southmead Hospital, Bristol.
been traditional to monitor peak and trough concen-Interpretative problems trations, much as for the aminoglycosides. However, because the bactericidal action of vancomycin is quite A minor laboratory problem relates to inactivation of gentamicin in vitro in the presence of ticarcillin and some different from that of the aminoglycosides, many have questioned the need to measure peak concentrations [31] . other b-lactam antibiotics [23] . The effect is to lower the measured concentration of the aminoglycoside. The
Vancomycin, like b-lactam antibiotics, works best if the concentration at the site of activity is maintained above longer the time interval between collection and measurement, the greater the effect. Interaction between aminog-the minimum inhibitory concentration (MIC) throughout the dose interval (so called time-dependent killing). This lycosides and ticarcillin is due to drug complexing and can occur if the two drugs are mixed in a syringe or profile argues against the need for peak concentration measurement, and suggests that a continuous infusion may giving set. Such mixing should be avoided.
be the ideal. In practice, a continuous infusion is rarely administered, and spaced dosing at 6 or 12 h intervals is Cost effectiveness/benefits of monitoring more common [31] . Efficacy can usually be assumed if the trough concentration is sufficiently above the MIC Monitoring of aminoglycoside concentrations, particularly with effective dose prediction, has been shown to be of the infecting organism. It is likely, although unproven, that toxicity is related cost-effective [24, 25] . Once-daily aminoglycoside dosing is cheaper than multiple-daily dosing in terms of nursing to total vancomycin exposure. It would seem logical to monitor some index of vancomycin accumulation, such time and infusion equipment and may require less monitoring, although the exact strategy for monitoring as a trough concentration. has yet to be established [26] . It is possible that total daily doses of aminoglycoside lower than those used tradition-Therapeutic ranges ally may prove to be effective. If so, toxicity will inevitably be less, and the need for monitoring will also Many putative 'therapeutic ranges' are illusionary. This is the case with vancomycin, at least for peak concentrations. be less. It may be that, except in certain specific circumstances such as rapid fluctuations in renal function
Ranges for peak concentrations of 20-40 mg l −1 have been widely quoted, but with little supportive evidence. or impaired renal function, no monitoring is necessary. However, the conclusion that monitoring is unnecessary
The original report of Geraci et al. [32] suggested that peaks greater than 50 mg l −1 should be avoided, based is premature. on two cases of ototoxicity at concentrations greater than 80 mg l −1 . Repetitive citation of this paper in the Vancomycin literature has resulted in the 'establishment' of the peak concentration strategy. One of the problems with peak Therapeutic drug monitoring is frequently employed during vancomycin therapy. Many have questioned the concentration measurement is that the range is meaningless unless the timing of sampling is also stated. A peak need for this, especially in uncomplicated patients with normal renal function [27] [28] [29] . However, most authors concentration of 40 mg l −1 has an entirely different meaning if it is from a sample taken just after the end of agree that monitoring is often useful. the infusion or from a sample taken 1 or 2 h later. A survey of Australasian hospitals indicated that peaks were Pharmacokinetics sampled from immediately post-infusion to 3 h later and yet were all considered with reference to the same The pharmacokinetics of vancomycin are relatively simple, with low protein binding, renal elimination with therapeutic range of 20-40 mg l −1 [31]. The folly of this is obvious. In summary, there is little justification for no metabolism, and no pharmacogenetic problems. V is around 0.4 l kg −1 and the CL approximates that of peak concentration measurement except for use in pharmacokinetic modelling. glomerular filtration rate. t 1/2 is approximately 6 h in patients with normal renal function [2]. A complicating A stronger but incomplete case can be made for trough concentration monitoring. The given range of feature is that the pharmacokinetic profile is best described by a 2-or 3-compartment model which makes calcu-5-10 mg l −1 has reasonable literature support and reflects the need for the concentration of antibiotics to be above lations difficult with a handheld calculator.
the MIC of the organism for the duration of the dose interval. Concentrations below the MIC have been Why monitor vancomycin?
associated with therapeutic failure. The MIC of vancomycin is approximately 1.5 mg l −1 for many susceptible Vancomycin has a low therapeutic index, with nephrotoxicity and ototoxicity complicating therapy [30] . It has organisms. The protein binding of vancomycin is approximately 50% which would argue that the minimum As with aminoglycosides, the clinical state may be changing during the early part of therapy. The timing of total concentration should be at least 3 mg l −1 . Trough concentrations above 10 mg l −1 have been associated repeat sampling depends on the clinical circumstances. If very high doses are being used, or if the clinical condition with an increased risk of nephrotoxicity [30, 33, 34] . It should be noted that nephrotoxicity with vancomycin is changing rapidly, sampling should be more frequent. alone is not common, usually around 5%, and is usually reversible [33] . A range of 5-10 mg l −1 for trough Methods of analysis concentrations appears to have some validity.
As with the aminoglycosides, vancomycin is generally analysed using immunoassays such as EMIT or FPIA. For Individualisation of therapy research purposes vancomycin is also analysed by h.p.l.c. [44] . The limit of quantification for the EMIT assay is Approaches to dosing of vancomycin have included 5 mg l −1 and 2.0 mg l −1 for FPIA. Quality control empirical, nomogram, individualised, and Bayesian programs are the same as for the aminoglycosides. methods [35] . It is generally accepted that vancomycin should be administered by slow infusion (for at least 1 h) to avoid the 'red man syndrome' [36] .
Interpretative problems Empirical methods usually involve administration of a Vancomycin degrades spontaneously at 37°C [45] . An total daily dose in adults of 2 g daily in 2-4 divided inactive metabolic product (CDP-1) accumulates in some doses. The relationship between vancomycin clearance circumstances (eg. marked renal failure and patients on and renal function has enabled dosing guidelines to take dialysis) and is detected by non-specific assays such as renal function into account [37] . This process has been FPIA [46] . refined into nomograms such as those of Matzke et al. [38] and Moellering et al. [39] .
Cost-effectiveness/benefits of monitoring Individualised dosing methods based on the approach of Sawchuk & Zaske [14] for aminoglycosides have been Information about the true cost-effectiveness of monitorused with varying success. The approach is based on a ing of vancomycin is lacking. One study demonstrated a one-compartment model, and may lead to underestimdecrease in nephrotoxicity associated with a therapeutic ation of the AUC [40] . At steady state this is unlikely to drug monitoring service [47] and another has demoncreate significant error. Bayesian predictive models have strated cost savings related to a monitoring service [48] . also been used [41, 42] . They require a minimal number of samples, and can accommodate 1-or 2-compartment Teicoplanin models. Pryka et al. [43] found that the 2-compartment model had less bias and more precision in non steady-Teicoplanin, like vancomycin, is a glycopeptide antibiotic which acts in a time-dependent manner. Its pharmaco-state situations, but once steady-state had been achieved the performance for the two models was similar. From a kinetics include a V of around 1 l kg −1 , protein binding of 90% and a prolonged terminal t 1/2 of 150 to 180 h, practical point of view, the individualised and Bayesian methods are probably equally useful at achieving target which is important during long term therapy [49] . Teicoplanin is cleared unchanged renally, and doses concentrations and subtle differences are unimportant [35] . There is far greater uncertainty about what the should be reduced appropriately in patients with renal dysfunction. Dose-related nephrotoxicity and ototoxicity target concentrations of vancomycin should be. appears to be much less of a problem than with vancomycin [50] .
Many methods have been used to quantify teicoplanin concentrations but none is entirely satisfactory for routine The lack of support for peak concentration measurement suggests that only trough concentrations should be clinical monitoring. [49] . FPIA is the most convenient method, but it may not be accurate at low concentrations monitored. Trough concentrations should be measured just prior to the next dose, within half an hour of the [51] . Therapeutic drug monitoring of teicoplanin is performed occasionally to ensure efficacy. Trough con-end of the dosage interval. If pharmacokinetic modelling is contemplated, the measurement of another concen-centrations of >10 mg l −1 have been recommended for most infections and >20 mg l −1 for endocarditis [52] . tration is required early in the dose interval. A trough concentration is all that is necessary for Bayesian
Monitoring has been advocated particularly in patients who have high clearance, such as children [53] . 'Red forecasting. The exact timing of the sampling is unimportant but needs to be known for interpretation.
man syndrome' appears to be much less of a problem with teicoplanin than with vancomycin [54] . The question of how often to sample is also important. total concentration of 1000 mg l −1 for the parent plus Antifungal agents active metabolite hydroxyitraconazole, has also been recommended [63] . Adverse effects related to itraconazole Individualisation of antifungal therapy has been proposed and reviewed [52, 55] . No specific recommendations are largely gastrointestinal and appear to be dose-related. A problem during therapeutic drug monitoring is that have been developed, although under certain circumstances, drug monitoring may assist therapy. The case for concentrations are assay-dependent, with the metabolite being recorded as parent in non specific microbiological monitoring is perhaps strongest for flucytosine and itraconazole. There may be a case for occasional assays. The preferred method of analysis is h.p.l.c., preferably with both parent and metabolite assessed [64] . monitoring of other azoles, such as ketaconazole and fluconazole, to ensure that adequate concentrations are Further work is necessary before the place of therapeutic drug monitoring for the therapy of itraconazole is achieved. As is the case with all therapeutic drug monitoring, if it provides an answer to a clearcut question, firmly established. then it is worthwhile.
Conclusion

Flucytosine
Aminoglycosides should continue to be monitored until it is clear that there are circumstances where monitoring Flucytosine is a synthetic antifungal agent that is selectively is unnecessary. Justification for vancomycin monitoring converted by fungal cells to fluorouracil which replaces is less clear, and there may be circumstances, such as uracil thereby disturbing protein synthesis. Flucytosine is short courses and short dose intervals in relatively well absorbed, with a V similar to that of body water uncomplicated patients, in which monitoring may not be and it is eliminated unchanged through the kidneys.
necessary. For the other drugs it is likely that monitoring Doses should be appropriately adjusted for renal dysfuncis only feasible in larger teaching hospitals where expertise tion [56] . Monitoring with flucytosine is not so much to is available for useful interpretation. ensure adequate concentrations for efficacy but to avoid toxicity. At high concentrations, bone marrow toxicity (usually reversible) has been reported [57].
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